In the context of MPM, which is treated in first-line therapy with cisplatin and antifolates, editing of the 3′-UTR may protect dihydrofolate reductase (DHFR) mRNA from mir-25-3p- and miR-125-3p-induced degradation, leading to resistance to antifolates such as methotrexate and pemetrexed, as it has been recently observed in breast cancer cells [115]. Here, DHFR is linked to breast carcinoma.